Moleculin Biotech (MBRX) Competitors $0.57 +0.05 (+9.70%) Closing price 07/9/2025 04:00 PM EasternExtended Trading$0.57 -0.01 (-1.05%) As of 06:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MBRX vs. LPCN, CING, MTEX, GELS, CARM, MRKR, CTXR, RVPH, PMN, and GOVXShould you be buying Moleculin Biotech stock or one of its competitors? The main competitors of Moleculin Biotech include Lipocine (LPCN), Cingulate (CING), Mannatech (MTEX), Gelteq (GELS), Carisma Therapeutics (CARM), Marker Therapeutics (MRKR), Citius Pharmaceuticals (CTXR), Reviva Pharmaceuticals (RVPH), Promis Neurosciences (PMN), and GeoVax Labs (GOVX). These companies are all part of the "pharmaceutical products" industry. Moleculin Biotech vs. Its Competitors Lipocine Cingulate Mannatech Gelteq Carisma Therapeutics Marker Therapeutics Citius Pharmaceuticals Reviva Pharmaceuticals Promis Neurosciences GeoVax Labs Moleculin Biotech (NASDAQ:MBRX) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends. Is MBRX or LPCN more profitable? Lipocine's return on equity of -26.68% beat Moleculin Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Moleculin BiotechN/A -278.80% -100.11% Lipocine N/A -26.68%-24.77% Do analysts prefer MBRX or LPCN? Moleculin Biotech presently has a consensus price target of $4.00, suggesting a potential upside of 599.30%. Lipocine has a consensus price target of $9.00, suggesting a potential upside of 180.37%. Given Moleculin Biotech's higher probable upside, research analysts plainly believe Moleculin Biotech is more favorable than Lipocine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moleculin Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Lipocine 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of MBRX or LPCN? 15.5% of Moleculin Biotech shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 1.9% of Moleculin Biotech shares are owned by insiders. Comparatively, 6.4% of Lipocine shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media prefer MBRX or LPCN? In the previous week, Moleculin Biotech had 3 more articles in the media than Lipocine. MarketBeat recorded 4 mentions for Moleculin Biotech and 1 mentions for Lipocine. Moleculin Biotech's average media sentiment score of 0.56 beat Lipocine's score of 0.00 indicating that Moleculin Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moleculin Biotech 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lipocine 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable earnings & valuation, MBRX or LPCN? Lipocine has higher revenue and earnings than Moleculin Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMoleculin BiotechN/AN/A-$21.76MN/AN/ALipocine$11.20M1.53$10K-$1.02-3.15 Which has more volatility and risk, MBRX or LPCN? Moleculin Biotech has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500. Comparatively, Lipocine has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500. SummaryMoleculin Biotech and Lipocine tied by winning 5 of the 10 factors compared between the two stocks. Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBRX vs. The Competition Export to ExcelMetricMoleculin BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.37M$2.90B$5.51B$8.95BDividend YieldN/A2.44%5.25%4.04%P/E RatioN/A21.0128.0220.16Price / SalesN/A246.40405.99173.08Price / CashN/A41.8337.0657.97Price / Book0.327.868.125.62Net Income-$21.76M-$54.96M$3.16B$248.50M7 Day Performance63.43%5.27%3.14%4.49%1 Month Performance-13.60%3.78%3.48%7.03%1 Year Performance-83.13%5.85%34.05%21.07% Moleculin Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBRXMoleculin Biotech3.0714 of 5 stars$0.57+9.7%$4.00+599.3%-82.4%$7.37MN/A0.0020News CoverageGap UpHigh Trading VolumeLPCNLipocine1.5677 of 5 stars$3.16-4.0%$9.00+184.8%-58.4%$17.60M$11.20M-3.1010CINGCingulate2.7104 of 5 stars$4.07+0.5%$26.00+538.8%+1,116.8%$17.19MN/A-0.4820News CoverageMTEXMannatech0.2897 of 5 stars$9.35+3.9%N/A+18.8%$17.11M$117.87M-93.50250Gap UpHigh Trading VolumeGELSGelteqN/A$1.73-4.4%N/AN/A$17.08M$100K0.00N/AGap UpCARMCarisma Therapeutics2.3948 of 5 stars$0.39-2.2%$1.93+391.6%-64.8%$16.74M$19.63M-0.2520MRKRMarker Therapeutics3.6748 of 5 stars$1.53+4.8%$13.17+760.6%-63.4%$16.52M$6.59M-1.1560Gap UpCTXRCitius Pharmaceuticals2.4401 of 5 stars$1.59+3.9%$53.00+3,233.3%-89.5%$16.27MN/A0.0020High Trading VolumeRVPHReviva Pharmaceuticals2.4528 of 5 stars$0.38+12.9%$9.00+2,261.6%-67.5%$16.20MN/A-0.485High Trading VolumePMNPromis Neurosciences3.3661 of 5 stars$0.48+0.7%$4.50+830.1%-82.4%$15.70MN/A-9.685GOVXGeoVax Labs3.4 of 5 stars$0.87-9.8%$11.10+1,182.2%-74.1%$15.29M$3.95M-0.2410Analyst RevisionGap Up Related Companies and Tools Related Companies LPCN Competitors CING Competitors MTEX Competitors GELS Competitors CARM Competitors MRKR Competitors CTXR Competitors RVPH Competitors PMN Competitors GOVX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MBRX) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting—or plan to collect—Social Security, this could be a game-changer. A new initiative tie...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MBRX Stock Alerts